Apealea (paclitaxel micellar) is a patented, water-soluble, intravenously injectable formulation of paclitaxel, a key chemotherapy agent used to treat many cancer types. Apealea is developed with Vivesto’s proprietary drug delivery platform XR-17, which enhances paclitaxel’s solubility. It was previously approved in the EU for treating adult patients experiencing their first relapse of platinum-sensitive epithelial ovarian cancer, primary peritoneal cancer, and fallopian tube cancer, in combination with carboplatin. Apealea has also received orphan drug designation in the U.S. for epithelial ovarian cancer.
Vivesto is actively seeking new global or regional partners for Apealea. In 2025, Vivesto signed a license agreement with Zhejiang Zhida Pharmaceutical Ltd in China for the development, production, and commercialization of Apealea in China, Hong Kong, Macao, and Taiwan. The deal includes upfront and milestone payments totaling up to $5.85 million, as well as sales royalties.